Inhibition of the enzyme purine nucleoside phosphorylase (PNP) reduces refractoriness to transfused platelets in a dog model
- 1 August 1990
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 75 (4) , 591-597
- https://doi.org/10.1111/j.1365-2141.1990.tb07804.x
Abstract
To better define the role of T-cells in alloimmunization, we induced purine nucleoside phosphorylase (PNP) deficiency in a dog platelet transfusion model. Short-term administration of eight different drug schedules using several combinations of the PNP inhibitor 8-aminoguanosine and/or deoxyguanosine did not induce significant toxicity in four treated animals as demonstrated by blood chemistries, cell counts, and autologous platelet recovery and survival measurements. However, continuous long-term daily administration of these agents produced significant renal and/or hepatic toxicity leading to death in five of six animals. Modification of the drug schedule to early short-term administration of both deoxyguanosine and 8-aminoguanosine, followed by long-term intermittent doses of only 8-aminoguanosine, was not only well tolerated by all the animals but also resulted in significant immunosuppression. Overall, six of nine evaluable dogs (67%) treated with some combination of PNP inhibitors did not become refractory to eight weekly transfusions of platelets from a single random donor dog. P < 0.005, compared to untreated controls, only 3/21 (14%) not immunized. Furthermore, in four evaluable recipients, discontinuation of the 8-aminoguanosine while continuing platelet transfusions from their original donors did not result in refractoriness. In addition, these four recipients were also unable to recognize platelets from two other random donors. This suggests that both specific and non-specific tolerance to foreign platelet antigens had been induced by PNP-inhibitor therapy. Other evidence for the efficacy of this immunosuppressive treatment was the almost normal post-transfusion recovery and survival of donor platelets, both during and after treatment. This suggests failure to form even low levels of platelet alloantibodies in the immunosuppressed recipients. In contrast, B-cell immunity to soluble antigens was intact as demonstrated by a normal antibody response to keyhole limpet haemocyanin (KLH) antigen.This publication has 21 references indexed in Scilit:
- Approaches to preventing or reversing platelet alloimmunization using animal modelsTransfusion, 1988
- SPECIFIC TOLERANCE AND IMMUNOCOMPETENCE IN HAPLOIDENTICAL, BUT NOT IN COMPLETELY ALLOGENEIC, CANINE CHIMERAS TREATED WITH METHOTREXATE AND CYCLOSPORINETransplantation, 1987
- Canine platelet alloimmunization: the role of donor selectionBritish Journal of Haematology, 1986
- Nucleoside kinases in T and B lymphoblasts distinguished by autoradiography.Proceedings of the National Academy of Sciences, 1986
- PROLONGATION OF SKIN GRAFT SURVIVAL IN DOGS TREATED WITH 8-AMINOGUANOSINETransplantation, 1986
- The metabolism of deoxyguanosine and guanosine in human B and T lymphoblasts. A role for deoxyguanosine kinase activity in the selective T-cell defect associated with purine nucleoside phosphorylase deficiencyBiochemical Journal, 1983
- Cyclosporin A – Usefulness, Risks and Mechanism of ActionImmunological Reviews, 1982
- Hemolysis in mice treated with deoxycoformycin, am inhibitor of adenosine deaminaseBiochemical Pharmacology, 1980
- NUCLEOSIDE-PHOSPHORYLASE DEFICIENCY IN A CHILD WITH SEVERELY DEFECTIVE T-CELL IMMUNITY AND NORMAL B-CELL IMMUNITYThe Lancet, 1975
- ADENOSINE-DEAMINASE DEFICIENCY IN TWO PATIENTS WITH SEVERELY IMPAIRED CELLULAR IMMUNITYThe Lancet, 1972